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Abstract 
 There are many different opposing studies about respiratory distress and how it 
affects premature infants as well as adults. The main focus is on how infants can be 
treated of acute respiratory distress syndrome or ARDS, which is more common when 
they are born prematurely. This analytical review is designed to capture all the past and 
present data in order to present both sides of controversy in the different treatments to 
treat respiratory distress in premature infants. The data finds that inhaled nitric oxide 
(iNO) is one of the main treatments for respiratory distress and has had a lot of 
controversy over the years. Most of the research points to the usefulness of iNO in 
different doses, although it is controversial as to the right dose amount. There are also a 
few other treatment possibilities that still need further research. iNO is useful as a 
treatment, and could be a temporary treatment before other treatments can be 
administered. However, it still has different risks involved especially when dealing with 
infants.  
Introduction and Background  
Acute Respiratory Distress Syndrome can be common in newborns as well as 
adults causing different breathing complications. It’s a common and devastating clinical 
syndrome that affects both medical and surgical patients. It is a lung condition where 
fluid collects in the lungs air sacs, which deprives the body and other organs of oxygen. It 
was first called the adult respiratory distress syndrome, but now the acute respiratory 
distress syndrome, since it does occur in children. In 1988, an expanded definition was 
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proposed that quantified the physiologic respiratory impairment through the use of a four-
point lung-injury scoring system that was based on the level of positive end-expiratory 
pressure, the ratio of the partial pressure of arterial oxygen to the fraction of inspired 
oxygen, the static lung compliance, and the degree of infiltration evident on chest 
radiographs. Other factors included in the assessment were the inciting clinical disorder 
and the presence or absence of nonpulmonary organ dysfunction (Ware et al. 2000).  
Although the lung-injury scoring system has been widely used to quantify the 
severity of lung injury in both clinical research and clinical trials, it cannot be used to 
predict the outcome during the first 24 to 72 hours after the onset of the acute respiratory 
distress syndrome and thus has limited clinical usefulness. When the scoring system is 
used four to seven days after the onset of the syndrome, scores of 2.5 or higher may be 
predictive of a complicated course with the need for prolonged mechanical ventilation 
(Ware et al. 2000). The purpose of this paper is to analyze all the different techniques and 
treatments for premature newborns with respiratory failure and/or respiratory distress 
syndrome, as well as the underlying controversy of these treatments or ways to prevent 
the disease itself.  
 
How to Help Premature Babies with Respiratory Distress 
Possible Treatments:  
A study was done regarding the value of lung ultrasound as early diagnostic tools 
in Respiratory Distress Syndrome, or RDS. The study found that were was a significant 
correlation between ultrasound and radiographic assessments of RDS. It found out that 
chest ultrasounds cannot replace standard chest x-rays in diagnosing potential causes of 
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neonatal respiratory failure because of its tendency to over estimate RDS, but are useful 
at excluding RDS as a screening method for diagnosis. It found that chest ultrasounds are 
important to consider as a screening method. This is important in describing the way 
RDS can be diagnosed in infants as well as premature babies, because they have to be 
properly diagnosed before treatment can occur. These conclusions were made by using 
40 preterm neonatal patients that were admitted to the intensive care unit in Madina 
national hospital that were suffering with RDS. All the patients were subject to a full 
maternal history as well as laboratory investigations that were performed including blood 
count, blood sugar, chest x-rays and chest ultrasounds (Abdelsadek et al. 2015).  
Another study assessed the utility and compared the outcomes of infants that did not use 
nasal biphasic positive airway pressure (n-BiPAP). They used infants with RDS that were 
admitted to the hospital between 2002-2010 and treated them with n-BiPAP treatment 
protocol. The study found that increasing use of n-BiPAP was associated with reduced 
morbidity in infants with RDS, so this may be an ethically sound and sustainable way of 
generating knowledge about the disease as well as its treatment along with other 
treatments (Solevag et al. 2015). 
There are different treatments that can be given, that include low doses of nitric 
oxide. There was a study done that shows that the most important difference between 
their trial and previous studies is that they used a low dose of inhaled nitric oxide for a 
limited amount of time (a maximum of 96 hours). Other trials have used higher doses (80 
ppm) for longer periods (as long as two weeks). By limiting the duration of treatment, 
they hoped to avoid delaying extracorporeal membrane oxygenation beyond the point at 
which its efficacy might be reduced. The data, combined with the results of previous 
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studies, suggest that this approach is effective. In the neonatal inhaled nitric oxide (iNO) 
study, neonates who did not have a response to 20 ppm of nitric oxide had a response to 
80 ppm. The median duration of successful treatment in this study was 44 hours, and all 
but two neonates were weaned from nitric oxide by 96 hours (Clark et al. 2000). 
A study done to asses the association between serum levels of 25-hydroxyvitamin 
D (25OHD) and the outcomes in preterm infants. They found a high prevalence of low 
25OHD, and they also found an association between the status of vitamin D and acute 
respiratory morbidity in preterm infants after birth. They did this by measuring the serum 
in mothers and their infants within 24 hours after birth. This study can possibly lead to 
the idea that maybe a higher prevalence of vitamin D could help against respiratory 
distress and can be similar to how vitamin A supplements are used and then just different 
vitamin supplements in general. The study demonstrated a significant association 
between vitamin D status and acute respiratory morbidity in infants after birth. 
Maintaining adequate maternal vitamin D levels during pregnancy is important in 
optimizing an infant’s vitamin D status at birth (Onwuneme et al. 2015).  
Other research discusses how premature infants are at an increased risk of 
wheezing with association to different respiratory problems like respiratory syncytial 
virus (RSV) and rhinovirus infections. The study found that wheezing lower respiratory 
diseases or WLRD risk had no increased evidence following routine vaccinations of 
premature infants. The study found no evidence of increased risk of medically attended 
WLRD among premature infants following routine vaccinations. The risk of WLRD 
among premature infants that were non-fragile appeared to be reduced for a few weeks 
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after vaccinations. If there is the possibility of vaccinating infants so that they are at less 
of a risk of respiratory problems this could be a great advantage (Mullooly et al. 2011).  
Something also that’s important to distinguish is the area of infants and adults and their 
differing affects to the distress. Treatments for infants vs. adults due to their differing 
affects to the distress is also an important area of research, because there are differences 
where it can be useful in adults and maybe not in infants.  
A study demonstrates the feasibility of administering low-dose glucocorticoid 
therapy and measuring clinically relevant outcomes in pediatric acute respiratory distress 
syndrome. Changes in oxygenation and/or ventilation are consistent with early acute 
respiratory distress syndrome pathophysiology and results of similar clinical trials in 
adults. Consistent with earlier adult studies and reported cases in pediatric patients with 
ARDS they found higher Pao2 /Fio2 ratios (of oxygen) in the steroid group on days 8 and 
9 (after 7 days of steroid infusion) and fewer patients required supplemental oxygen at 
PICU transfer. Pao2 is the partial pressure of arterial oxygen and Fio2 is the fraction of 
inspired oxygen. They speculated that steroid therapy may have reduced lung 
inflammation, and they launched efforts to examine inflammatory markers in these 
patients. Unlike the adult clinical trials or pediatric cases reported. Higher plateau 
pressures occurred in the steroid group at enrollment, suggesting poorer compliance than 
placebo group, but lower Pao2 values on days 2 and 3 and higher pH on day 2 in the 
steroid group could indicate a decrease in dead space ventilation (Drago et al. 2015). 
There are treatments of inhaled nitric oxide therapies that are also useful in helping 
infants/premature babies with ARDS and respiratory problems, and these other possible 
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treatments are also candidates to be used along with iNO possibly where iNO is a rescue 
intervention to buy more time for other treatment to be done.  
Use of iNO and other supplement treatments:  
 
In preterm infants, inhaled nitric oxide (iNO) improves gas exchange in infants 
with respiratory distress syndrome and persistent pulmonary hypertension. In animal 
models, iNO reduces lung inflammation and oxidant stress that cause acute lung injury in 
preterm infants. iNO maintains surfactant activity and improves lung structure in 
experimental models of bronchopulmonary dysplasia (BPD). BPD is a form of chronic 
lung disease that affects newborns, mostly premature ones. It results from damage to the 
lungs that are caused by mechanical ventilation and/or long-term oxygen. Despite 
favorable preclinical studies, the effects of iNO for the prevention of human BPD have 
been variable. In 2 randomized control studies, iNO therapy improved pulmonary 
outcomes and survival in preterm newborns born.  The separate effects of iNO therapy 
and vitamin A supplementation have been studied in animal models and human studies, 
but in no previous study have authors examined the effects of the combination of both of 
these therapies in preterm newborns at risk for BPD. Ongoing postnatal deficiency of 
vitamin A in very low birth weight preterm infants may promote chronic lung disease by 
impairing lung healing, contributing to the loss of cilia, increasing epithelial cell 
metaplasia and susceptibility to infection, and decreasing the number of alveoli in lung 
parenchyma. Although exact mechanisms by which iNO reduces risk of BPD are 
uncertain, nitric oxide decreases neutrophil adhesion in microcirculation, which may 
attenuate the inflammatory cascade that contributes to lung injury and BPD in the 
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preterm infant (Gadhia et al. 2014). The mechanisms of this therapy are important to 
discuss in order to better understand how nitric oxide affects the bodies of these infants.  
 
Inhaled Nitric Oxide (iNO)  
Mechanisms:  
Mechanisms through which inhaled nitric oxide therapy might provide 
neuroprotection in the premature newborn are uncertain. A possible explanation is that 
inhaled nitric oxide modulates circulating cells (including neutrophils, monocytes, and 
platelets) as they transit the pulmonary circulation; the down-regulation of lung-derived 
cytokines that is induced by inhaled nitric oxide may also reduce the injury of distant 
organs. Another possible mechanism may relate to the distal delivery to the central 
nervous system of nitric oxide or nitric oxide–related metabolites through the systemic 
circulation through pathways mediated by red cells or proteins (Kinsella et al. 2006). 
There is controversy over the topic and whether or not iNO is useful and what other 
vasodilator can be used, some found it useful while others did not (Adhikari et al. 2014). 
Current Research and Controversy of iNO:  
 
The response of dosage shows that the lowest dose is the more effective 
treatment. There was a study done on a multicenter randomized controlled trial of inhaled 
nitric oxide for pediatric acute respiratory distress syndrome. It found that iNO led to a 
significant reduction in the duration of mechanical ventilation. Previous studies of iNO in 
pediatric ARDS were either designed with or allowed for a crossover to iNO, precluding 
an analysis on the impact of iNO on outcomes in pediatric ARDS. The most common 
precipitating cause for ARDS in adults is sepsis, but in children it is pneumonia, and 
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there are likely differences in the organisms responsible for these diseases (Bronicki et al. 
2014).  
The main finding is that iNO does not reduce hospital mortality in patients with 
Acute Respiratory Distress Syndrome or ARDS, regardless of the severity of hypoxemia. 
In the study the effects of iNO did not differ between more hypoxemic and less 
hypoxemic patients. Most of the trials did not measure oxygenation index, an alternative 
measure of hypoxemia that incorporates mean airway pressure as a marker of the 
intensity of mechanical ventilation. The number of patients in the severe ARDS subgroup 
was relatively small, limiting the statistical power of our analysis to detect true 
differences in mortality between subgroups. Clinicians can argue that the dose used in 
included studies was insufficient to improve gas exchange in the most severely 
hypoxemic patients, who would be expected to be at highest risk from imminent death 
due to hypoxemia.  
However, the trials included in this review suggest otherwise. Of the trials that 
titrated NO to achieve improved oxygenation (50–53), the lowest and most effective dose 
was 5–10 ppm in three trials and ~13 ppm in the fourth trial. These findings are 
consistent with a detailed dose-response study that found that the average increase in of 
the oxygen level in the blood that is breathed was maximal at 5 ppm (Adhikari et al. 
2014). 
The study done was able to show a clear dose as a response relationship for this 
very preterm group of infants. Considering the results of this study within the context of 
other similar studies they advised the use of the lowest effective dose possible in any 
clinical application. Where no pulmonary vasodilator response is seen at any dose but 
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there is a clinical decision to continue with inhaled nitric oxide, iNO. Analysis of the 
infant characteristics at trial entry between responders and non-responders showed only 
that male infants were more likely to show a clinical response than female infants. Given 
the small study size this difference, although statistically significant, may still represent a 
chance finding. The high patient variance indicated that there was great variability in how 
different infants responded to the dosing but little variability within a single infant. 
Statistical analysis of the results indicated no convincing evidence of a dose response 
effect once the effect of period and infant variability was taken into account. 
Coordinators of future randomized trials of iNO in this high-risk population should 
continue to consider the value of further dose—response studies to add to these data for a 
technique that must still be viewed as experimental in the preterm infant (Ahluwalia et al.  
2006). New research should really focus on finding out more about these treatments and 
what dosage is really useful.  
 
Future research of iNO 
There is other research that should be conducted and what still needs clarification 
to know more about treatments. The processes underlying preterm birth are poorly 
understood. The incidence and the underlying causes of preterm birth are known to vary 
geographically and temporally. Environmental exposures, such as pollution and tobacco 
smoke, and individual behavioral differences also contribute.  Interference with the 
fetus’s natural environment during critical windows of development causes many 
different affects. The processes underlying preterm birth challenge the developmental 
plasticity of the lungs and airways. Common antecedents of preterm birth such as 
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inflammation, maternal smoking, metabolic derangement, hypoxia, and growth restriction 
have well-recognized adverse effects on lung maturation and structure, T cell polarization 
and development, and airway reactivity.  Such alterations can differentially affect 
susceptibility of the lungs to injurious exposures that commonly follow preterm birth, 
including sepsis, respiratory infections, mechanical ventilation, and hyperoxia. Preterm 
birth furthermore augments the association of several of these risk factors, such as 
antenatal inflammation and smoke exposure, with childhood wheezing.  Genetic 
influences and gene–environment interactions are furthermore likely to play a role, and 
the link between preterm birth and asthma has been suggested to at least partially reflect a 
common genetic background (Been et al. 2014).  
Pulmonary vasodilator study done on lambs to test reversing of hypoxic 
pulmonary vasoconstriction as another treatment possibility. This study demonstrates that 
iNO can act as a selective local pulmonary vasodilator without causing systemic 
vasodilation. iNO reversed the pulmonary hypertension caused by infusing the stable 
endoperoxide analogue U46619 without decreasing systemic arterial pressure.  Eight 
Suffolk lambs weighing 25-35 kg underwent a sterile thoracotomy to place a left atrial 
line, a tracheostomy, and a femoral artery line under general endotracheal anesthesia with 
halothane and oxygen 3 days before the study. After this recovery period, the lambs 
underwent sterile placement of a 7F thermodilution pulmonary artery monitoring catheter 
(Edwards Laboratories, Santa Ana, Calif.) through a jugular vein under local anesthesia. 
At all dose levels, iNO produced a prompt reduction of the pulmonary hypertension 
caused by U46619 infusion.They believe rapid combination with hemoglobin in red 
blood cells inactivates iNO, restricting iNO vasodilation to vessels in the lung and 
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preventing systemic vasodilation (Frotell et al.1991). Along with all this future research 
that needs should be conducted and is being conducted now because some of this 
research is from the early 90s, the different risks for treatment of iNO should also be 
taken into consideration.  
 
Risks of iNO 
Pediatric intensivists all over the world are challenged in predicting which child 
with pediatric acute respiratory distress syndrome (PARDS) is destined to die. Identifying 
a child with a high likelihood of mortality is important in counseling families, in guiding 
therapeutic decisions, and in designing studies intended to evaluate the efficacy of novel 
therapies. In their recent publication, the acute lung injury consensus conference 
(PALICC) reviewed mortality rates in PARDS from 1992 to 2013 in multiple 
observational and epidemiologic studies and discovered a range of 10–50% in those 
inclusive of over 100 children (Anas 2016). 
The risks involved in using inhaled nitric oxide with fears of damage to cells in 
ventilated preterm infants. There have been fears that iNO could increase free radical 
damage to cells. This is a particular concern in ventilated preterm infants already under 
considerable oxidative stress and with compromised anti-oxidant defenses. A randomized 
controlled trial of treatment with iNO therapy and/or intravenous dexamethasone in 
preterm infants at risk of developing chronic lung disease (CLD) was performed. This 
pilot study was designed to look for evidence of increased lipid peroxidation after iNO.  
Urine and breath samples were collected before treatment commenced and 6, 24, 48 and 
72 hours after beginning therapy in treated and control subjects. Urinary 
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malondialdehyde (uMDA) was measured by HPLC, and breath pentane by GC with 
thermal desorption. Gestation and birth weight were similar in both groups. There were 
no statistical differences in outcome measures between treated and non-treated infants. 
The pre-treatment pentane exhalation rate was similar in the two groups studied. Study 
ultimately found the difference in the risk to be insignificant and iNO does not increase 
lipid peroxidation, which involves cell damage that is caused by free radicals (Drury et al.  
1998). Different risks do not just affect babies when they are born but can also affect 
them long term as well.  
Later in Life Impacts and Controversy with iNO 
Long term effects of iNO: 
 
In animal models, iNO decreases baseline airway resistance and may increase the 
rate of alveolarization. To date of the study, only 2 studies have reported respiratory 
outcomes of preterm infants treated with iNO. In a telephone survey that included 456 
infants in the Nitric Oxide Chronic Lung Disease (NOCLD) study group, the use of 
bronchodilators, inhaled steroids, systemic steroids, diuretics, and supplemental oxygen 
during the first year of life was less in the iNO-treated group. There are no significant 
differences in the frequency of wheezing or the rate of rehospitalization. In the Inhaled 
Nitric Oxide Versus Ventilatory Support Without Inhaled Nitric Oxide multicenter trial, 
follow-up at 1 year of age showed no difference in maximal expiratory flow at functional 
residual capacity, wheezing, readmission rate, or use of respiratory medications (Kumar 
2014).  
In recent years new and interesting effects of iNO, in addition to improving 
oxygenation, have been observed in animals and people. These effects may modify 
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pathophysiological events in the lung during respiratory distress. Early administration of 
iNO has been shown to be anti-inflammatory, to be anti-proliferative on vascular smooth 
muscle cells, and to promote normal lung development. It is now known that iNO after 
pulmonary absorption can be transported outside the lung and used in redox-based 
signaling and some extrapulmonary effects may be undesirable, such as reversible 
changes in kidney function (Lindwall et al. 2005).  
 
Effects of early school age of iNO: 
 
At 2 years of age, iNO-treated premature infants in our study had approximately 
half the risk of cognitive impairment exhibited by the placebo-treated group, since there 
was a control (placebo) and then a group that was administered nitric oxide. This marked 
difference in cognitive impairment was not apparent at school age indicates that factors 
outside the neonatal period, such as the home environment and socioeconomic status, 
become increasingly important as infants acquire more complex repertoires of skills and 
behaviors. To assess whether beneficial effects of iNO treatment during prematurity 
persisted to early school age, first they compared the incidences of chronic morbidities 
between groups. There were no significant differences between groups in the percentage 
of children having one or no chronic morbidities. Significantly fewer iNO-treated infants 
had multiple chronic morbidities or were dependent on technology compared with 
placebo-treated infants and because the presence of multiple chronic morbidities or 
dependence on technology strongly reduces the likelihood of school readiness, these data 
suggest that, by decreasing the total morbidity burden, iNO may decrease the number of 
premature children requiring additional societal resources (Patrianakos-Hoobler et al. 
2011) 
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 A relook at a study done over 20 years ago on iNO and vasodilation: 
 
The study published in 1993 was one of the first to provide evidence for selective 
pulmonary vasodilation produced by breathing NO in adult ARDS patients. It offered the 
advantage of lowering the elevated pulmonary artery pressures, improving arterial 
oxygenation, and protecting the right ventricle from failure without reducing systemic 
arterial resistance or pressure. iNO proved superior to classical intravenous vasodilators 
in ARDS, since breathing NO reduced and did not increase the pulmonary right-to-left 
shunt fraction. Researchers studying ARDS never demonstrated an improved outcome 
with iNO treatment. However, breathing iNO is still used to buy time to institute other 
therapies in severely hypoxemic ARDS. Maybe now that low volume ventilation has 
become standard therapy in ARDS, a trial of breathing iNO to improve the outcome of 
ARDS patients should be considered. Future research may yield synergistic beneficial 
effects in terms of outcome between iNO and other advanced ARDS treatment modules 
(Rossaint et al. 2014).  
Another study found this to be ineffective though through other testing in iNO. 
iNO as rescue therapy for the very ill ventilated preterm infant does not appear to be 
effective and may increase the risk of severe interventricular hemorrhage (IVH) 
(Barrington et al. 2010). So, in the current era of protective mechanical ventilation, some 
clinicians employ iNO breathing for a period of 24–48 hours as a rescue intervention for 
severely hypoxemic patients to buy time and allow other therapies like Extracorporeal 
Membrane Oxygenation (ECMO) or prone positioning to improve the patients’ 
pulmonary gas exchange (Rossaint et al. 2014). 
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The current controversy of different treatment options:   
 
The study found that low-dose inhaled nitric oxide reduced the incidence of 
bronchopulmonary dysplasia in infants with a birth weight of 1000 g or more. There was 
no significant reduction in the incidence of bronchopulmonary dysplasia among infants 
with lower birth weights. Various factors other than inhaled nitric oxide, including the 
stage of lung development at birth, influence the need for supplemental oxygen at 36 
weeks of postmenstrual age. The multifactorial nature of lung injury and repair at the 
extremes of prematurity may limit the efficacy of any single intervention, and the 
targeting of 36 weeks of postmenstrual age for an evaluation of the pulmonary reparative 
capacity of newborns with extremely low birth weights may not be an adequate end point 
(Kinsella et al. 2006).  
Another study investigates antenatal steroid treatment and postnatal surfactant 
replacement therapy and was completed by reviewing 70 complete autopsies. Then the 
lung tissues were examined and graded. They were put in control and experimental 
groups with the treatment being the mother getting the surfactant and the steroid. The 
study found that there was a significant reduction in the severe hyaline membrane that 
was associated with combined surfactant and antenatal steroid therapy. However the 
cause for the similar incidence of the selected histopathological findings in the treatment 
groups and the control could be linked to oxygen toxicity due to insufficient antioxidant 
capacity in premature infants and barotrauma from mechanical ventilation. While the 
study found all this information it could lead to controversy since the findings were not 
found to be significant in the study, however they did not find this surprising because 
they excluded patients who were successfully treated and discharged so it is hard to relate 
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these findings to treatment regimens, possibly a better study would invite the discharged 
patients back to get tested on (Teksam et al. 2009). This is another possible treatment 
instead of iNO that could be administered as inhaled steroids, but hopefully the use of 
iNO would reduce the need for using this kind of treatment.  
Conclusion 
This research topic interested me significantly because I was born ten weeks 
prematurely, and it seems that there is still a lot of research that needs to be done on the 
affects of premature birth and possible treatments that can help. This is a good step in that 
direction even though there is still some controversy on the topic of iNO being a good 
treatment method, as it having side affects in the long run possibly. Having to get a 
cesarean section or just a natural premature birth can cause problems to the baby, as well 
as the mother having been sick, so it an important field to continue to study and learn 
more about.  
Different research options should be looked into more as well such as the 
vaccines and supplemental vitamins that can help prevent respiratory distress in infants.  
Some studies are contradicting, although also important to note the span of time from the 
90s until now that all of these studies have occurred in, now there is better medicine and 
babies are born earlier and earlier but with risk of more complications. There is still 
uncertainty of mechanisms of treatments, and with lots of trial and error, may only be 
useful in severe cases otherwise would not want to risk using some treatments. There are 
still risks with iNO and these treatments, especially since the mechanism is still not fully 
understood or how much of the dosage of the treatment is necessarily effective in every 
case.  
17
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